Multiple roles of dihomo-γ-linolenic acid against proliferation diseases

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Wang, Xiaoping ^a   Lin, Huanping ^a   Gu, Yan ^b  

^a SHAANXI UNIVERSITY OF CHINESE MEDICINE   (China)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Cancer; Differentiation; Dihomo linolenic acid (DGLA); Proliferation; Prostaglandin E1 (PGE1)

Indexed keywords

DIHOMO GAMMA LINOLENIC ACID; ICOSATRIENOIC ACID; LIPOXYGENASE; PROSTAGLANDIN E1; PROSTAGLANDIN SYNTHASE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL DIFFERENTIATION; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; INFLAMMATORY CELL; LIPID METABOLISM; NEOPLASM; NONHUMAN; REVIEW; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; INFLAMMATION; OXIDATION REDUCTION REACTION; PATHOLOGY;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; INFLAMMATION; NEOPLASMS; OXIDATION-REDUCTION;

EID: 84857016714     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-25     Document Type: Review

References (89)

1. The relationships between erythrocyte membrane n-6 to n-3 polyunsaturated fatty acids ratio and blood lipids and C-reactive protein in Chinese adults: an observational study. Zhang B, Wang P, Zhou Q, Chen C, Zhuo S, Ye Y, He Q, Chen Y, Su Y, Biomed Environ Sci 2011 24 234 242 21784308
2. Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. Gomolka B, Siegert E, Blossey K, Schunck WH, Rothe M, Weylandt KH, Prostaglandins Other Lipid Mediat 2011 94 81 87 10.1016/j.prostaglandins.2010.12.006 21236358
3. Essential Fatty acids-a review. Das UN, Curr Pharm Biotechnol 2006 7 467 482 10.2174/138920106779116856 17168664 (Pubitemid 46017539)
4. Essential fatty acids: biochemistry, physiology and pathology. Das UN, Biotechnol J 2006 1 420 439 10.1002/biot.200600012 16892270
5. Genetic variation of the FADS1 FADS2 gene cluster and n-6 PUFA composition in erythrocyte membranes in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Zietemann V, Kröger J, Enzenbach C, Jansen E, Fritsche A, Weikert C, Boeing H, Schulze MB, Br J Nutr 2010 104 1748 1759 10.1017/S0007114510002916 20691134
6. Effect of polyunsaturated fatty acids on drug-sensitive and resistant tumor cells in vitro. Das UN, Madhavi N, Lipids Health Dis 2011 10 159 10.1186/1476-511X-10-159 21917129
7. Polyunsaturated fatty acid metabolism in prostate cancer. Berquin IM, Edwards IJ, Kridel SJ, Chen YQ, Cancer Metastasis Rev 2011 30 295 309 10.1007/s10555-011-9299-7 22015690
8. Can essential fatty acids reduce the burden of disease(s)? Das UN, Lipids Health Dis 2008 7 9 10.1186/1476-511X-7-9 18348729 (Pubitemid 351464613)
9. Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, Hines OJ, Eibl G, Pancreas 2008 36 353 362 10.1097/MPA.0b013e31815ccc44 18437081 (Pubitemid 351591577)
10. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Astorg P, Cancer Causes Control 2004 15 367 386 15141138 (Pubitemid 38988026)
11. Engineering of a novel hybrid enzyme: an anti-inflammatory drug target with triple catalytic activities directly converting arachidonic acid into the inflammatory prostaglandin E2. Ruan KH, Cervantes V, So SP, Protein Eng Des Sel 2009 22 733 740 10.1093/protein/gzp058 19850676
12. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Kapoor R, Huang YS, Curr Pharm Biotechnol 2006 7 531 534 10.2174/138920106779116874 17168669 (Pubitemid 46017544)
13. The influence of feeding linoleic, gamma-linolenic and docosahexaenoic acid rich oils on rat brain tumor fatty acids composition and fatty acid binding protein 7 mRNA expression. Nasrollahzadeh J, Siassi F, Doosti M, Eshraghian MR, Shokri F, Modarressi MH, Mohammadi-Asl J, Abdi K, Nikmanesh A, Karimian SM, Lipids Health Dis 2008 7 45 10.1186/1476-511X-7-45 19014610
14. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Dommels YE, Haring MM, Keestra NG, Alink GM, van Bladeren PJ, van Ommen B, Carcinogenesis 2003 24 385 392 10.1093/carcin/24.3.385 12663496 (Pubitemid 36432632)
15. Similar antineoplastic effects of nimesulide, a selective COX-2 inhibitor, and prostaglandin E1 on B16-F10 murine melanoma cells. Tabolacci C, Lentini A, Provenzano B, Gismondi A, Rossi S, Beninati S, Melanoma Res 2010 20 273 279 10.1097/CMR.0b013e328339d8ac 20404772
16. Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Levin G, Duffin KL, Obukowicz MG, Hummert SL, Fujiwara H, Needleman P, Raz A, Biochem J 2002 365 489 496 10.1042/BJ20011798 11939906 (Pubitemid 36135320)
17. Importance of dietary gamma-linolenic acid in human health and nutrition. Fan YY, Chapkin RS, J Nutr 1998 128 1411 1414 9732298 (Pubitemid 28399935)
18. Cardioprotective effect of liposomal prostaglandin E1 on a porcine model of myocardial infarction reperfusion no-reflow. Li JH, Yang P, Li AL, Wang Y, Ke YN, Li XL, J Zhejiang Univ Sci B 2011 12 638 643 21796804
19. PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl - cyclodextrin (PGE1-HPCD) complex for the treatment of pulmonary arterial hypertension (PAH). Gupta V, Davis M, Hope-Weeks LJ, Ahsan F, Pharm Res 2011 28 1733 1749 10.1007/s11095-011-0409-6 21626061
20. Alpha-linolenic acid intake and 10-year incidence of coronary heart disease and stroke in 20,000 middle-aged men and women in the Netherlands. de Goede J, Verschuren WM, Boer JM, Kromhout D, Geleijnse JM, PLoS One 2011 6 17967 10.1371/journal.pone.0017967 21464993
21. Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. Bolton-Smith C, Woodward M, Tavendale R, Eur J Clin Nutr 1997 51 619 624 10.1038/sj.ejcn.1600455 9306089 (Pubitemid 27424976)
22. Dietary supplementation with -linolenic acid alters fatty acid content and eicosanoid production in healthy humans. Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fontech AN, Chilton FH, J Nutr 1997 127 1435 1444 9237935 (Pubitemid 27323451)
23. Trans-18:1 and CLA isomers in rumen and duodenal digesta of bulls fed n-3 and n-6 PUFA-based diets. Shen X, Dannenberger D, Nuernberg K, Nuernberg G, Zhao R, Lipids 2011 46 831 841 10.1007/s11745-011-3586-5 21739241
24. Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression. McNamara RK, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton JW, Schizophr Res 2011 129 57 65 10.1016/j.schres.2011.03.006 21458237
25. Effects of dietary -linolenic acid (18:3n-3)/linoleic acid (18:2n-6) ratio on fatty acid metabolism in Murray cod (Maccullochella peelii peelii). Senadheera SD, Turchini GM, Thanuthong T, Francis DS, J Agric Food Chem 2011 59 1020 1030 10.1021/jf104242y 21222433
26. Regulation of rat brain polyunsaturated fatty acid (PUFA) metabolism during graded dietary n-3 PUFA deprivation. Kim HW, Rao JS, Rapoport SI, Igarashi M, Prostaglandins Leukot Essent Fatty Acids 2011 85 361 368 10.1016/j.plefa.2011.08.002 21880477
27. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes.Monohydroxy acids from novel lipoxygenase. Borgeat P, Hamberg M, Samuelsson S, J Biol Chem 1976 251 7816 7820 826538 (Pubitemid 8015793)
28. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Simopoulos AP, Exp Biol Med (Maywood) 2008 233 674 688 10.3181/0711-MR-311
29. Plasma n-3 and n-6 fatty acids and the incidence of atrial fibrillation following coronary artery bypass graft surgery. Skuladottir GV, Heidarsdottir R, Arnar DO, Torfason B, Edvardsson V, Gottskalksson G, Palsson R, Indridason OS, Eur J Clin Invest 2011 41 995 1003 10.1111/j.1365-2362.2011.02497.x 21413975
30. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ, Nutr Res 2011 31 1 8 10.1016/j.nutres.2011.01.002 21310299
31. Polyunsaturated fatty acids sensitize human colon adenocarcinoma HT-29 cells to death receptor-mediated apoptosis. Hofmanová J, Vaculová A, Kozubík A, Cancer Lett 2005 218 33 41 10.1016/j.canlet.2004.07.038 15639338 (Pubitemid 40082699)
32. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Dupertuis YM, Meguid MM, Pichard C, Curr Opin Clin Nutr Metab Care 2007 10 427 432 10.1097/MCO.0b013e3281e2c9d4 17563460 (Pubitemid 46934111)
33. Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. Chamras H, Ardashian A, Heber D, Glaspy JA, J Nutr Biochem 2002 13 711 716 10.1016/S0955-2863(02)00230-9 12550055 (Pubitemid 35463199)
34. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Astorg P, Cancer Causes Control 2004 15 367 386 15141138 (Pubitemid 38988026)
35. COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. Cathcart MC, O'Byrne KJ, Reynolds JV, O'Sullivan J, Pidgeon GP, Biochim Biophys Acta 2012 1825 49 63 22015819
36. In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells. Zhong B, Cai X, Yi X, Zhou A, Chen S, Su B, J Steroid Biochem Mol Biol 2011 126 10 18 10.1016/j.jsbmb.2011.03.018 21458568
37. Cyclooxygenase-2 and gastric cancer. Thiel A, Mrena J, Ristimäki A, Cancer Metastasis Rev 2011 30 387 395 10.1007/s10555-011-9312-1 22002749
38. Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis. Talar-Wojnarowska R, Gasiorowska A, Olakowski M, Lampe P, Smolarz B, Romanowicz-Makowska H, Malecka-Panas E, World J Gastroenterol 2011 17 4113 4117 10.3748/wjg.v17.i36.4113 22039326
39. The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Sung YK, Hwang SY, Kim JO, Bae HI, Kim JC, Kim MK, Mol Cells 2004 17 35 38 15055524 (Pubitemid 39137041)
40. An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Mendes RA, Carvalho JF, Waal I, Oral Oncol 2009 45 124 e128 10.1016/j.oraloncology.2009.03.016 19457709
41. Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF - treated A549 cells. Sun L, Zhang S, Jiang Z, Huang X, Wang T, Huang X, Li H, Zhang L, Biochem Biophys Res Commun 2011 416 99 105 10.1016/j.bbrc.2011.11.004 22093832
42. Cyclooxygenases: structural, cellular, and molecular biology. Smith WL, DeWitt DL, Garavito RM, Annu Rev Biochem 2000 69 145 182 10.1146/annurev. biochem.69.1.145 10966456
43. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Garavito RM, DeWitt DL, Biochim Biophys Acta 1999 1441 278 287 10570255 (Pubitemid 29537747)
44. COX-2 inhibitors and metabolism of essential fatty acids. Das UN, Med Sci Monit 2005 11 A233 237 15990700
45. The role of the EP receptors for prostaglandin E(2) in skin and skin cancer. Rundhaug JE, Simper MS, Surh I, Fischer SM, Cancer Metastasis Rev 2011 30 465 480 10.1007/s10555-011-9317-9 22012553
46. Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer. Luo H, Chen Z, Jin H, Zhuang M, Wang T, Su C, Lei Y, Zou J, Zhong B, J Exp Clin Cancer Res 2011 30 6 10.1186/1756-9966-30-6 21219643
47. Prostaglandin E2 regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Fujino H, Toyomura K, Chen XB, Regan JW, Murayama T, Biochem Pharmacol 2011 81 379 387 10.1016/j.bcp.2010.11.001 21070749
48. COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer. Liu H, Yang Y, Xiao J, Lv Y, Liu Y, Yang H, Zhao L, Anat Rec (Hoboken) 2010 293 1838 1846 10.1002/ar.21240
49. Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect. Gao Y, Xu P, Chen L, Li Y, Int J Pharm 2010 387 263 271 10.1016/j.ijpharm.2009.12.019 20006690
50. Dietary lipid source alters murine macrophage/vascular smooth muscle cell interactions in vitro. Fan YY, Ramos KS, Chapkin RS, J Nutr 1996 126 2083 2088 8814195 (Pubitemid 26313584)
51. Prostanoid receptors and their biological actions. Negishi M, Sugimoto Y, Ichikawa A, Prog Lipid Rez 1993 32 417 434 10.1016/0163-7827(93)90017-Q (Pubitemid 24032718)
52. Cell cycle-dependent inhibition of DNA synthesis in vascular smooth muscle cells by prostaglandin E1: relationship to intracellular cAMP levels. Fan YY, Ramos KS, Chapkin RS, Prostaglandins Leukot Essent Fatty Acids 1996 54 101 107 10.1016/S0952-3278(96)90066-6 8848428 (Pubitemid 26109861)
53. (199) Transcription factors coupled to the cAMPsignalling pathway. Foulkes NS, Sasone-Corsi P, Biochim Biophys Acta 1996 1288 101 121
54. Anti-atherosclerotic effects of dihomo-gamma-linolenic acid in ApoE-deficient mice. Takai S, Jin D, Kawashima H, Kimura M, Shiraishi-Tateishi A, Tanaka T, Kakutani S, Tanaka K, Kiso Y, Miyazaki M, J Atheroscler Thromb 2009 16 480 489 10.5551/jat.No430 19713674
55. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Das UN, Lipids Health Dis 2008 7 37 10.1186/1476-511X-7-37 18922179
56. PGE1 and PGE2 modify platelet function through different prostanoid receptors. Iyú D, Jüttner M, Glenn JR, White AE, Johnson AJ, Fox SC, Heptinstall S, Prostaglandins Other Lipid Mediat 2011 94 9 16 10.1016/j.prostaglandins.2010.11.001 21095237
57. Prostaglandin E1, E2 and their metabolites. Kojima F, Yuhki K, Kashiwagi H, Ushikubi F, Nihon Rinsho 2010 68 20 24 20960741
58. Differential effects of prostaglandin E1 and prostaglandin E2 on growth and differentiation of murine myeloid leukemic cell line, M1. Sawamura H, Hayashi H, Onozaki K, Microbiol Immunol 1995 39 809 815 8577272
59. Gershwin ME:Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. Ziboh VA, Naguwa S, Vang K, Wineinger J, Morrissey BM, Watnik M, Clin Dev Immunol 2004 11 13 21 10.1080/10446670410001670445 15154607 (Pubitemid 38478560)
60. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Celotti F, Durand T, Prostaglandins Other Lipid Mediat 2003 71 147 162 10.1016/S1098-8823(03)00039-X 14518558 (Pubitemid 36929787)
61. Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Gregor JI, Kilian M, Heukamp I, Kiewert C, Kristiansen G, Schimke I, Walz MK, Jacobi CA, Wenger FA, Prostaglandins Leukot Essent Fatty Acids 2005 73 89 97 10.1016/j.plefa.2005.04.016 15964750 (Pubitemid 41008618)
62. A novel 15-hydroxyeicosatrienoic acid-substituted diacylglycerol (15-HETrE-DAG) selectively inhibits epidermal protein kinase C-beta. Cho Y, Ziboh VA, Biochim Biophys Acta 1997 1349 67 71 9421197 (Pubitemid 27517524)
63. Significance of lipoxygenase-derived monohydroxy fatty acids in cutaneous biology. Ziboh VA, Miller CC, Cho Y, Prostaglandins Other Lipid Mediat 2000 63 3 13 10.1016/S0090-6980(00)00093-9 11104337
64. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. Jiang WG, Hiscox S, Bryce RP, Horrobin DF, Mansel RE, Br J Cancer 1998 77 731 738 10.1038/bjc.1998.120 9514051 (Pubitemid 28077460)
65. Gamma-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells. Watkins G, Martin TA, Bryce R, Mansel RE, Jiang WG, Prostaglandins Leukot Essent Fatty Acids 2005 72 273 278 10.1016/j.plefa.2004. 12.004 15763439 (Pubitemid 40342999)
66. Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids. Jiang WG, Singhrao SK, Hiscox S, Hallett MB, Bryce RP, Horrobin DF, Puntis MC, Mansel RE, Clin Exp Metastasis 1997 15 593 602 10.1023/A:1018435229087 9344043 (Pubitemid 27435740)
67. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Menéndez JA, Ropero S, del Barbacid MM, Montero S, Solanas M, Escrich E, Cortés-Funes H, Colomer R, Breast Cancer Res Treat 2002 72 203 219 10.1023/A:1014968415759 12058962 (Pubitemid 34430002)
68. Gamma-linolenic acid induces apoptosis and lipid peroxidation in human chronic myelogenous leukemia K562 cells. Ge H, Kong X, Shi L, Hou L, Liu Z, Li P, Cell Biol Int 2009 33 402 410 10.1016/j.cellbi.2009.01.014 19356705
69. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R, Int J Oncol 2004 24 1369 1383 15138577
70. In vivo and in vitro biotransformation of the lithium salt of gamma-linolenic acid by three human carcinomas. de Antueno R, Elliot M, Ells G, Quiroga P, Jenkins K, Horrobin D, Br J Cancer 1997 75 1812 1818 10.1038/bjc.1997.309 9192987 (Pubitemid 27230709)
71. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Menendez JA, Ropero S, Lupu R, Colomer R, Oncol Rep 2004 11 1241 1252 15138562
72. Gamma-linolenic acid therapy of human glioma-a review of in vitro, in vivo, and clinical studies. Das UN, Med Sci Monit 2007 13 A119 131 17599036
73. Apoptosis. p53 and PUMA: a deadly duo. Vousden KH, Science 2005 309 1685 1686 10.1126/science.1118232 16151000 (Pubitemid 41285928)
74. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? Das UN, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P, Prostaglandins Leukot Essent Fatty Acids 1998 58 39 54 10.1016/S0952-3278(98) 90128-4 9482165 (Pubitemid 28053789)
75. The induction of apoptosis in human cervical carcinoma (HeLa) cells by gamma-linolenic acid. de Kock M, Lottering ML, Grobler CJ, Viljoen TC, le Roux M, Seegers JC, Prostaglandins Leukot Essent Fatty Acids 1996 55 403 411 10.1016/S0952-3278(96)90123-4 9014218 (Pubitemid 27014128)
76. Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells: relationship to free radicals and lipid peroxidation and its modulation by calmodulin antagonists. Sagar PS, Das UN, Koratkar R, Ramesh G, Padma M, Kumar GS, Cancer Lett 1992 63 189 198 10.1016/0304-3835(92)90260-3 1315618
77. Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells in vitro. Sagar PS, Das UN, Prostaglandins Leukot Essent Fatty Acids 1995 53 287 299 10.1016/0952-3278(95)90129-9 8577783
78. Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Harbige LS, Lipids 2003 38 323 341 10.1007/s11745-003-1067-z 12848277 (Pubitemid 36724289)
79. Cellular interactions between n-6 and n-3 fatty acids: a mass analysis of fatty acid elongation/desaturation, distribution among complex lipids, and conversion to eicosanoids. Rubin D, Laposata M, J Lipid Res 1992 33 1431 1440 1472257
80. Regulation of agonist-induced prostaglandin E1 versus prostaglandin E2 production. Rubin D, Laposata M, A mass analysis J Biol Chem 1991 266 23618 23623 (Pubitemid 21908842)
81. Apoptosis-inducing action of two products from oxidation of sesamol, an antioxidative constituent of sesame oil: a possible cytotoxicity of oxidized antioxidant. Fujimoto A, Shingai Y, Oyama TB, Kawanai T, Hashimoto E, Koizumi K, Kimura K, Masuda T, Oyama Y, Toxicol In Vitro 2010 24 1720 1726 10.1016/j.tiv.2010.05.013 20510349
82. Sesamin inhibits macrophage-induced vascular endothelial growth factor and matrix metalloproteinase-9 expression and proangiogenic activity in breast cancer cells. Lee CC, Liu KJ, Wu YC, Lin SJ, Chang CC, Huang TS, Inflammation 2011 34 209 221 10.1007/s10753-010-9226-z 20617373
83. Pharmacological modulation of fatty acid desaturation and of cholesterol biosynthesis in THP-1 cells. Risé P, Ghezzi S, Levati MG, Mirtini R, Colombo C, Galli C, Lipids 2003 38 841 846 10.1007/s11745-003-1134-5 14577663 (Pubitemid 37193745)
84. Induced oxidative stress and cell death in the A549 lung adenocarcinoma cell line by ionizing radiation is enhanced by supplementation with docosahexaenoic acid. Kikawa KD, Herrick JS, Tateo RE, Mouradian M, Tay JS, Pardini RS, Nutr Cancer 2010 62 1017 1024 10.1080/01635581.2010.492084 21058189
85. Antithrombotic potential of dihomo-gamma-linolenic acid in man. Kernoff PB, Willis AL, Stone KJ, Davies JA, McNicol GP, Br Med J 1977 2 1441 1444 10.1136/bmj.2.6100.1441 338112 (Pubitemid 8230392)
86. Subchronic (13-week) oral toxicity study of dihomo-gamma-linolenic acid (DGLA) oil in rats. Kawashima H, Toyoda-Ono Y, Suwa Y, Kiso Y, Food Chem Toxicol 2009 47 1280 1286 10.1016/j.fct.2009.03.001 19275928
87. Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats. Umeda-Sawada R, Fujiwara Y, Ushiyama I, Sagawa S, Morimitsu Y, Kawashima H, Ono Y, Kiso Y, Matsumoto A, Seyama Y, Biosci Biotechnol Biochem 2006 70 2121 2130 10.1271/bbb.60057 16960355 (Pubitemid 44451888)
88. Oral supplementation with dihomo-gamma-linolenic acid-enriched oil altered serum fatty acids in healthy men. Teraoka N, Kawashima H, Shiraishi-Tateishi A, Tanaka T, Nakamura J, Kakutani S, Kiso Y, Biosci Biotechnol Biochem 2009 73 1453 1455 10.1271/bbb.90112 19502748
89. Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Zurier RB, Rossetti RG, Jacobson EW, DeMarco DM, Liu NY, Temming JE, White BM, Laposata M, Arthritis Rheum 1996 39 1808 1817 10.1002/art.1780391106 8912502 (Pubitemid 26378572)